NOAH Statement on New Research into Spot-On Parasite Control Products
10th June 2025
NOAH Statement on New Research into Spot-On Parasite Control Products
NOAH is aware of a recent study investigating swimming emissions from dogs treated with spot-on parasite control products containing fipronil or imidacloprid. We are currently reviewing the findings in full.
Protecting both animal health and the environment is vital.
Parasite control is essential to animal health and welfare, preventing suffering and reducing the risk of zoonotic disease. The animal health industry remains committed to a thriving environment for all, driven by the principles of One Health which links animal, human, and environmental health.
NOAH supports a science-led, evidence-based approach to risk mitigation and regulatory decision-making. It is important however, that this is based on sound science that does not oversimplify complex issues or draw broad conclusions from limited data. The authors call for more data—but simultaneously recommend far-reaching regulatory changes based on evidence that is incomplete. By suggesting a blanket restriction on antiparasitic medicines without presenting viable alternatives or a robust evidence base, the paper risks damaging confidence in science-led regulation, and undermining animal health and welfare by compromising the availability of these products to the widest number of pet owners.
All veterinary medicines, including flea treatments and other antiparasitic medicines, marketed in the UK are subject to strict regulation. They must undergo an independent scientific assessment by the government’s Veterinary Medicines Directorate (VMD), before being allowed on the market and to be used by pet owners. This independent regulatory assessment and oversight considers the product’s quality, efficacy, and safety, including safety for pets, people, and the environment. The benefit-risk balance of products remains under ongoing, continuous regulatory review to ensure that it is appropriate for these products to remain on the market, for the health and welfare of animals.
Responsible use is key.
NOAH advocates for a risk-based approach to parasite control, informed by veterinary advice, to minimise any unintended impact. Companion animal treatments should be targeted and tailored to individual risk.
We recognise the need for engagement with pet owners on this issue and our ongoing “Use It Right, Treat Them Right” campaign highlights the importance of using veterinary medicines responsibly and in accordance with product labels and professional guidance from vets and SQPs, including avoiding swimming and bathing where advised.
NOAH will continue to work collaboratively with the vets and SQPs, retailers, regulators, and our member companies to review the evidence and promote best practice in the use of all veterinary medicines, including promoting responsible stewardship. Collaboration and open dialogue are essential to ensuring the continued availability of vital treatments while protecting the wider environment.